Daewon Pharmaceutical KRX:003220KOSPI
대원제약 · Korean news coverage and regulatory filings, organized.
In Q2 2026, Daewon Pharmaceutical reported revenue of ₩153bn, up 6.2% year on year, and an operating loss of ₩9m. Daewon Pharmaceutical (대원제약) appeared in 36 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 23 with 31 articles. The most common catalyst was clinical & approvals (12). It was most often mentioned alongside Dong-A Socio Holdings, SK Bioscience and Humedix.
Filing signals Clinical trial filing Screener
Daewon Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩153bn | +6.2% | −₩9m margin −0.0% | ₩3.8bn |
| Q1 2026 | ₩158bn | +0.1% | ₩4.4bn margin 2.8% | ₩1.9bn |
| Q4 2025 derived | ₩160bn | +10.2% | ₩5.9bn margin 3.7% | ₩12.6bn |
| Q3 2025 | ₩144bn | -8.2% | −₩10.4bn margin −7.2% | −₩18.0bn |
| Q2 2025 | ₩144bn | +4.3% | −₩1.4bn margin −1.0% | −₩3.5bn |
| Q1 2025 | ₩158bn | -0.3% | ₩9.4bn margin 6.0% | ₩4.9bn |
| Q4 2024 derived | ₩145bn | +3.0% | ₩3.2bn margin 2.2% | −₩3.3bn |
| Q3 2024 | ₩157bn | +21.6% | ₩11.4bn margin 7.3% | ₩5.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Daewon Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Daewon Pharmaceutical news Korean headlines
-
Major대원제약 P-CAB 신약 임상 3상 성공…연내 허가 신청 전망
1 more on this story · 1 outlets
- 대원제약 파도프라잔 3상 성공…연내 허가 신청재경일보 · 08:50
-
대원제약 이길호 상무 모친상
5 more on this story · 5 outlets
- 대원제약 이길호 상무 모친상메디파나뉴스 · Oct 27 14:12
- 이길호 대원제약 상무 모친상메디팜스투데이 · Oct 27 14:22
- [부음] 대원제약 이길호 상무 모친상지디넷코리아 · Oct 27 14:24
- [부음] 이길호 대원제약 상무 모친상코메디닷컴 · Oct 27 15:23
- 대원제약 이길호 상무 모친상보건신문 · Oct 27 19:22
-
대원제약 “경구 비만약 후보물질, 흡수율 3배 높였다”
1 more on this story · 1 outlets
- 대원제약 “경구 비만약 후보물질, 흡수율 3배 높였다”조선일보 · Oct 23 14:15
-
대원제약, 경구용 세마글루타이드 흡수율 개선...2027년 임상 추진
1 more on this story · 1 outlets
- 대원제약, 경구용 세마글루타이드 흡수율 개선…2027년 임상 추진EBN · Oct 23 15:48